| Gao, Zhiliang |
NCT04201808: Efficacy and Safety of TAF in Patients With Suboptimal Response to Other Nucleos(t)Ides |
|
|
| Recruiting | 4 | 100 | RoW | Tenofovir Alafenamide 25 MG, Vemlidy | New Discovery LLC, Beijing Ditan Hospital | Hepatitis B, Chronic | 09/23 | 09/23 | | |
NCT04147208: Evaluate the Safety, Tolerability, and Antiviral Activity of GLS4 With Ritonavir in Patients With Chronic HBV Infection |
|
|
| Completed | 2 | 250 | RoW | GLS4, Morphothiadine Mesilate Capsules, RTV, Ritonavir tablet, ETV, Entecavir table | Sunshine Lake Pharma Co., Ltd. | Chronic HBV Infection | 06/22 | 09/23 | | |
| Zhang, Qi |
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD) |
|
|
| Active, not recruiting | 4 | 8250 | RoW | Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy | Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases | 04/25 | 04/25 | | |
NCT05224960: Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-2) |
|
|
| Recruiting | 2 | 140 | RoW | UC-MSCs, Placebo(solution without UC-MSCs) | Beijing 302 Hospital, Chinese PLA General Hospital, Shanghai Changzheng Hospital, LanZhou University, Jin Yin-tan Hospital, Hainan Hospital of Chinese PLA General Hospital, Vcanbio Cell and Gene Engineering Corp., Ltd., Third Affiliated Hospital, Sun Yat-Sen University, Xinjiang Kashi Area Number 1 Hospital | Decompensated Cirrhosis | 06/25 | 06/27 | | |
NCT06461624: Clinical Trial of Autologous GPC3 CAR-T Cells (CBG166) Therapy for Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | 1 | 15 | RoW | anti-GPC3 CAR-T, CBG166 CAR-T | Zhejiang University, Carbiogene Therapeutics Co. Ltd. | Advanced Hepatocellular Carcinoma | 07/27 | 10/27 | | |
| Not yet recruiting | N/A | 220 | RoW | Paclitaxel-Eluting Coronary Balloon Dilation Catheter (DIOR), Paclitaxel-Eluting Balloon (Bingo) | CCRF Inc., Beijing, China | Percutaneous Coronary Intervention | 05/22 | 10/22 | | |
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System |
|
|
| Not yet recruiting | N/A | 2150 | RoW | Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy | Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Heart Disease | 01/26 | 01/28 | | |
| Peng, Liang |
NCT06301854: Long-term Safety of TPN171H Tablet in Erectile Dysfunction. |
|
|
| Recruiting | 3 | 472 | RoW | TPN171H, Simmerafil | Vigonvita Life Sciences | Erectile Dysfunction | 04/25 | 04/25 | | |
| Recruiting | 2 | 116 | RoW | Placebo, TQA3334 Tablet, Nucleoside (acid) analogs (NAs) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Hepatitis B | 12/25 | 06/26 | | |
NCT06452693: A Clinical Study to Evaluate the Efficacy of TQA3038 Injection in Patients With Chronic Hepatitis B |
|
|
| Not yet recruiting | 1/2 | 162 | RoW | TQA3038 injection/placebo, Nucleotide drugs Control group | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Hepatitis B, Chronic | 09/26 | 09/26 | | |
NCT04665362: IIT Study of M1-c6v1 Combined With SHR-1210 and Apatinib in Patients With HCC |
|
|
| Not yet recruiting | 1 | 10 | NA | Recombinant oncolytic virus M1, anti PD-1 antibody, Apatinib | Liang Peng, Guangzhou Virotech Pharmaceutical Co., Ltd. | Advanced/Metastatic Hepatocellular Carcinoma | 06/22 | 10/22 | | |
| Gu |
NCT06683651: A Study in Chinese Patients With Acquired Blepharoptosis |
|
|
| Recruiting | 3 | 180 | RoW | STN1013800 ophthalmic solution, STN1013800 ophthalmic solution Liquid Base, without STN1013800 | Santen Pharmaceutical Co., Ltd. | Blepharoptosis | 06/26 | 06/26 | | |
NCT05508100: Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors |
|
|
| Completed | 1 | 38 | RoW | IO-108, IO-108 + pembrolizumab, IO-108 + Keytruda®, IO-108 + tislelizumab | Immune-Onc Therapeutics | Advanced Solid Tumor | 04/24 | 04/24 | | |
| Zheng, Yubao |
NCT04201808: Efficacy and Safety of TAF in Patients With Suboptimal Response to Other Nucleos(t)Ides |
|
|
| Recruiting | 4 | 100 | RoW | Tenofovir Alafenamide 25 MG, Vemlidy | New Discovery LLC, Beijing Ditan Hospital | Hepatitis B, Chronic | 09/23 | 09/23 | | |
| Xu, Bixin |
NCT04201808: Efficacy and Safety of TAF in Patients With Suboptimal Response to Other Nucleos(t)Ides |
|
|
| Recruiting | 4 | 100 | RoW | Tenofovir Alafenamide 25 MG, Vemlidy | New Discovery LLC, Beijing Ditan Hospital | Hepatitis B, Chronic | 09/23 | 09/23 | | |
| Zeng, Guofen |
| No trials found |
| Ren, Jie |
| No trials found |
| Xu, Wenxiong |
| No trials found |
